These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 17468372)

  • 21. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
    Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
    Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glitazones more than hypoglycemics in type 2 diabetes].
    Sjöholm A
    Lakartidningen; 2007 Oct 24-30; 104(43):3201-3. PubMed ID: 18018938
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
    Charbonnel B
    Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    Nathan DM; Buse JB; Davidson MB; Ferrannini E; Holman RR; Sherwin R; Zinman B
    Diabetes Care; 2008 Jan; 31(1):173-5. PubMed ID: 18165348
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
    Donnelly R
    Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Polonsky T; Mazzone T; Davidson M
    Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659
    [No Abstract]   [Full Text] [Related]  

  • 30. [Is there a need of glitazones in the treatment of diabetes?].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Aug; 127(16):2124; author reply 2124. PubMed ID: 17717584
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological interventions in the prevention of type 2 diabetes.
    Henness S
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):166-9. PubMed ID: 17940436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of type 2 DM: implications for adolescents and young adults.
    Karam JG; McFarlane SI
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():980-8. PubMed ID: 18806714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
    Charbonnel B
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():19-20. PubMed ID: 18001315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Don't judge all glitazones alike!].
    Sjöholm A
    Lakartidningen; 2007 Oct 24-30; 104(43):3205. PubMed ID: 18018940
    [No Abstract]   [Full Text] [Related]  

  • 36. [Three studies in type 2 diabetes: DREAM the wash-out results].
    Roussel R
    Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():36-8. PubMed ID: 17961660
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 38. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Glitazones--again].
    Halse J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2707; author reply 2707. PubMed ID: 17952161
    [No Abstract]   [Full Text] [Related]  

  • 40. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.